SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait that limits reproduction of male and female rats. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
IPO Year: 2016
Exchange: NASDAQ
Website: senestech.com
D - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
10-Q - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
S-8 - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
8-K - SenesTech, Inc. (0001680378) (Filer)
424B5 - SenesTech, Inc. (0001680378) (Filer)
PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye
PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GOVX) shares moved upwards by 21.71% to $2.27. The market value of their outstanding shares is at $5.2 million. NexImmune (NASDAQ:NEXI) stock increased by 9.52% to $3.45. The company's market cap stands at $4.7 million. As per the news, the Q1 earnings report came out 2 days ago. Cognition Therapeutics (NASDAQ:CGTX) stock rose 8.04% to $2.83. The market value of their outstanding shares is at $113.3 million. Clearside Biomedical (NASDAQ:CLSD) shares rose 7.39% to $1.45. The market value of t
HC Wainwright & Co. analyst Amit Dayal reiterates SenesTech (NASDAQ:SNES) with a Buy and maintains $3.5 price target.
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
PHOENIX, Aug. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today the closing of an exercise of certain existing warrants to purchase 505,502 shares of the Company's common stock at a reduced exercise price of $4.60 per share. In addition, the Company issued new warrants, as described below. The aggregate gross proceeds from the exercise of the existing warrants were approximately $2.3 million, before deducting placement agent fees and other offering expenses payable by the Company.
Record Revenue and Margin Performance PHOENIX, Aug. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the second quarter of 2024. Recent Highlights Record revenues of $874,000 in the first half of 2024, an increase of 62% compared to the first half of 2023.Gross margin percentages improved to 54% during Q2 2024 compared to 47% in Q1 2024
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Aug. 1, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its second quarter 2024, ended June 30, 2024, after the market close on Thursday, August 8, 2024. The Company has scheduled a conference call that same day, Thursday, August 8, 2024, at 5:00 pm ET, to review the results. Second Quarter 2024 Conference Call Details Date and Time: Thursday, August 8, 2024, at 5:00 pm ET Call-in Information: Interested parties can access the confere
LOS ANGELES, July 31, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The GotStocks Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives responsible for guiding gems that could be on the cusp of huge moves. The latest episode features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ:SNES), the leader in fertility control to manage animal pest
Common Stock Will Begin Trading on a Split-Adjusted Basis on July 25, 2024 PHOENIX, July 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))) (www.senestech.com) the leader in fertility control to manage animal pest populations, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:01 p.m, Eastern Time, on July 24, 2024. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "SNES" and will begin trading on a split-adjusted basis when the market opens on July 25,
PHOENIX, June 26, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the leader in fertility control to manage animal pest populations, today announced that Evolve™, the Company's minimum risk soft bait for the proactive control of rats, will be deployed in the U.S Virgin Islands as part of an international effort to control invasive species in environmentally sensitive areas. This effort is administered by the Wild Ecology Group. "The Wild Ecology Group sees Evolve as part of a long term, sustainable solution to invasive species prolife
MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteMed
MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 48
PHOENIX, May 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) today announced that Joel Fruendt, Chief Executive Officer, and Tom Chesterman, Chief Financial Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Company Webcast The webcasted presentation will take place at 11:45am ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or direc
PHOENIX, May 22, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the leader in fertility control to manage animal pest populations, today announced that it has taken a significant step forward in the distribution of EvolveTM, the Company's minimum risk soft bait for the proactive control of rats, through the launch of a dedicated online store on Amazon, the world's largest online retailer. To purchase Evolve on Amazon, please visit this link. "Evolve isn't just a product; it's a paradigm shift in pest control," declares Joel Fruendt,
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G - SenesTech, Inc. (0001680378) (Subject)
SC 13G - SenesTech, Inc. (0001680378) (Subject)
SC 13G - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
Record Revenue and Margin Performance PHOENIX, Aug. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the second quarter of 2024. Recent Highlights Record revenues of $874,000 in the first half of 2024, an increase of 62% compared to the first half of 2023.Gross margin percentages improved to 54% during Q2 2024 compared to 47% in Q1 2024
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Aug. 1, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its second quarter 2024, ended June 30, 2024, after the market close on Thursday, August 8, 2024. The Company has scheduled a conference call that same day, Thursday, August 8, 2024, at 5:00 pm ET, to review the results. Second Quarter 2024 Conference Call Details Date and Time: Thursday, August 8, 2024, at 5:00 pm ET Call-in Information: Interested parties can access the confere
PHOENIX, May 9, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the first quarter of 2024. Recent Highlights Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023.Evolve™, formulated especially for the control of rat fertility and launched at the beginning of the year, has quickly become the Company'
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, May 2, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its first quarter 2024, ended March 31, 2024, after the market close on Thursday, May 9, 2024. The Company has scheduled a conference call that same day, Thursday, May 9, 2024, at 5:00 pm ET, to review the results. First Quarter 2024 Conference Call Details Date and Time: Thursday, May 9, 2024, at 5:00 pm ET Call-in Information: Interested parties can access the conference call by
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Feb. 15, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its fourth quarter and fiscal year 2023, ended December 31, 2023, after the market close on Wednesday, February 21, 2024. The Company has scheduled a conference call that same day, Wednesday, February 21, 2024, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2023 Conference Call Details Date and Time: Wednesday, February 21, 2024, at 5:00 pm ET Call-in Infor
July 2023 Sales Increased 126% as New Initiatives Take Hold Expanded Product Offerings Expected to Drive Future Growth PHOENIX, Aug. 10, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced financial results for the second quarter of 2023 for the period ended June 30, 2023. "We successfully executed against a number of key strategic imperatives to drive long-term growth in Co
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Aug. 3, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its second quarter 2023, ended June 30, 2023, after the market close on Thursday, August 10, 2023. The Company has scheduled a conference call that same day, Thursday, August 10, 2023, at 5:00 pm ET, to review the results. Second Quarter 2023 Conference Call Details Date and Time: Thursday, August 10, 2023, at 5:00 pm ET Call-in Information: Interested parties can access the conf
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, May 4, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its first quarter 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023. The Company has scheduled a conference call that same day, Thursday, May 11, 2023, at 5:00 pm ET, to review the results. First Quarter 2023 Conference Call Details Date and Time: Thursday, May 11, 2023, at 5:00 pm ET Call-in Information: Interested parties can access the conference call
Product Sales Break $1 Million Sales Increase 77% for the Year PHOENIX, March 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2022 financial results, with products sales increasing 77% compared to the prior year. Joel Fruendt, SenesTech's new Chief Executive Officer, commented, "Breaking $1 million is a tremendous milestone. This was fueled in part by considerable
Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, March 8, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) will report financial results for its fourth quarter and fiscal year 2022, ended December 31, 2022, after the market close on Thursday, March 16, 2023. The Company has scheduled a conference call that same day, Thursday, March 16, 2023, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2022 Conference Call Details Date and Time: Thursday, March 16, 2023, at 5:00 pm ET Call-in Information: Inte